AJP - Endocrinology and Metabolism, Vol 259, Issue 3 E457-E461, Copyright © 1990 by American Physiological Society

ARTICLES

Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro

D. A. Young, R. O. Deems, R. W. Deacon, R. H. McIntosh and J. E. Foley
Diabetes Department, Sandoz Research Institute, Sandoz Pharmaceuticals, East Hanover, New Jersey 07936.

The effects of amylin on glucose metabolism and glycogenolysis were examined in vivo and in vitro. Eighteen-hour-fasted rats were infused with 5 nmol.kg-1.min-1 amylin and [3-3H]glucose for 120 min. Blood glucose levels increased an average of 45% during the infusion. Glucose turnover measurements indicated that the overall rate of glucose appearance (Ra) did not change, but the metabolic clearance rate of glucose was decreased by 42%. Samples of liver, gastrocnemius, and soleus muscles were freeze-clamped at the end of the infusion period and analyzed for glycogen and glucose 6-phosphate levels. Glycogen levels were decreased in all tissue samples, whereas glucose 6-phosphate was elevated in gastrocnemius and soleus muscles. Isolated soleus muscles were incubated in vitro with 200 microU/ml of insulin and 1, 10, or 100 nM amylin. Amylin treatment had no effect on 3-O-methyl-D-glucose transport; however, 2-deoxy-D-glucose uptake was inhibited by 33 or 48% at 10 or 100 nM amylin, respectively. Glycogen levels were also decreased after treatment with 10 and 100 nM amylin. Glucose 6-phosphate levels were not affected by amylin treatment in the presence of insulin but were increased nearly twofold in its absence. The data suggest that amylin stimulates glycogenolysis and inhibits glucose uptake both in vivo and in vitro and that the inhibition of glucose uptake is due to inhibition of glucose phosphorylation (i.e., hexokinase).

This article has been cited by other articles:

				Y. Wang, A. Xu, J. Ye, E. W. Kraegen, C. A. Tse, and G. J.S. Cooper Alteration in Phosphorylation of P20 Is Associated With Insulin Resistance Diabetes, August 1, 2001; 50(8): 1821 - 1827. [Abstract] [Full Text] [PDF]

				A. L. Castle, C.-H. Kuo, D.-H. Han, and J. L. Ivy Amylin-mediated inhibition of insulin-stimulated glucose transport in skeletal muscle Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E531 - E536. [Abstract] [Full Text] [PDF]

				R. O. Deems, R. C. Anderson, and J. E. Foley Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys Am J Physiol Regulatory Integrative Comp Physiol, February 1, 1998; 274(2): R524 - R528. [Abstract] [Full Text] [PDF]

				A. L. Castle, C.-H. Kuo, and J. L. Ivy Amylin influences insulin-stimulated glucose metabolism by two independent mechanisms Am J Physiol Endocrinol Metab, January 1, 1998; 274(1): E6 - E12. [Abstract] [Full Text] [PDF]

				M. Hettiarachchi, S. Chalkley, S. M. Furler, Y.-S. Choong, M. Heller, G. J. S. Cooper, and E. W. Kraegen Rat amylin-(8---37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E859 - E867. [Abstract] [Full Text] [PDF]

				W. M. Macfarlane, S. C. Campbell, L. J. Elrick, V. Oates, G. Bermano, K. J. Lindley, A. Aynsley-Green, M. J. Dunne, R. F. L. James, and K. Docherty Glucose Regulates Islet Amyloid Polypeptide Gene Transcription in a PDX1- and Calcium-dependent Manner J. Biol. Chem., May 12, 2000; 275(20): 15330 - 15335. [Abstract] [Full Text] [PDF]